Phase II study of epirubicin in advanced malignant melanoma

Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were obse...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1984-01, Vol.2 (3), p.315-317
Main Authors: Lopez, M, Perno, C F, Papaldo, P, Di Lauro, L, Ganzina, F, Barduagni, A
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - therapeutic use
Blood - drug effects
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Drug Evaluation
Epirubicin
Female
Heart - drug effects
Humans
Male
Melanoma - drug therapy
Middle Aged
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were observed. Nausea and vomiting and alopecia were common. Mild to moderate leukopenia occurred in 6 patients. Three cases of reversible ST-T changes were recorded. The observed response rate of 5% with a 39.2% probability of a true response rate greater than or equal to 10%, does not suggest that epirubicin, in the dose and schedule chosen, is active in metastatic malignant melanoma.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00175383